Breaking News Instant updates and real-time market news.

ICUI

ICU Medical

$125.96

0.26 (0.21%)

, PFE

Pfizer

09:31
10/06/16
10/06
09:31
10/06/16
09:31

ICU Medical to acquire Hospira Infusion Systems Business from Pfizer for $1B

ICU Medical (ICUI) and Pfizer (PFE) announced earlier that they have entered into a definitive agreement under which ICU Medical will acquire all of Pfizer's global infusion therapy business, Hospira Infusion Systems, for $1B in cash and stock. The Hospira Infusion Systems business includes IV pumps, solutions, and devices that, when combined with ICU Medical's existing businesses, will create a leading pure-play infusion therapy company, with estimated pro forma combined revenues of approximately $1.45B based on trailing twelve month results as of June 2016. Under the terms of the agreement, Pfizer will receive approximately $400M in newly issued shares of ICU Medical common stock and $600M in cash from ICU Medical subject to customary adjustment for net working capital. Upon completion of the transaction, which the companies expect to occur in the first quarter of 2017 subject to customary closing conditions including required regulatory approvals, Pfizer will own approximately 16.6% of ICU Medical. In addition, so long as Pfizer continues to hold 10% or more of ICU Medical's common equity, it will have the right to nominate one director to the company's board of directors in ICU Medical's proxy materials, and Pfizer has agreed to certain restrictions on transfer of its shares for at least 18 months.

ICUI

ICU Medical

$125.96

0.26 (0.21%)

PFE

Pfizer

  • 07

    Oct

  • 01

    Nov

ICUI ICU Medical
$125.96

0.26 (0.21%)

01/14/16
PIPR
01/14/16
NO CHANGE
Target $129
PIPR
Overweight
Piper views potential Pfizer divestment as neutral for ICU Medical
Piper Jaffray analyst Thomas Gunderson views Bloomberg's report that Pfizer (PFE) may be considering a sale of the infusion pump division of the recently acquired Hospira as neutral for ICU Medical (ICUI). Hospira has traditionally been ICU's largest customer, which has some worrying that if the infusion pumps are sold once again, the business could be at risk, Gunderson tells investors in a research note. He believes, however, that a Pfizer divestment could bring some upside to ICU since the infusion pump business is not in the pharma giant's "wheelhouse." Gunderson keeps an Overweight rating on ICU Medical with a $129 price target.
03/11/16
GABE
03/11/16
INITIATION
GABE
Buy
ICU Medical initiated with a Buy at Gabelli
08/09/16
ROTH
08/09/16
NO CHANGE
Target $132
ROTH
Buy
ICU Medical Direct sales momentum continues, says Roth Capital
Roth Capital analyst Chris Lewis says ICU Medical delivered a Q2 beat and raised its 2016 outlook as Direct sales momentum and OEM/Hospira growth continued. Although the company expects an even steeper decline in Hospira over the second half of 2016, the analyst believes ICU Medical is well-positioned to sustain revenue growth on Direct strength and non-Hospira OEM channels, with margin expansion opportunities materializing in 2017. Lewis reiterates a Buy rating on the stock and raised his price target on the shares to $132 from $130.
PFE Pfizer

08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.

TODAY'S FREE FLY STORIES

I

Intelsat

$3.73

-0.08 (-2.10%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Earnings
Intelsat backs FY17 revenue view $2.18B-$2.23B, consensus $2.19B »

Backs FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Earnings
Under Armour backs FY17 view for revenues growth of 11%-12% »

There are no changes to…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls narrows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

I

Intelsat

$3.73

-0.08 (-2.10%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Intelsat reports Q1 EPS (29c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Under Armour reports Q1 EPS (1c), consensus (4c) »

Reports Q1 revenue…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
L3 Technologies raises FY17 EPS view to $8.50-$8.70 from $8.40-$8.60 »

FY17 consensus $8.60.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AB

AllianceBernstein

$22.75

-0.05 (-0.22%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
AllianceBernstein reports Q1 EPS 46c, consensus 44c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
WEX sees Q2 adjusted EPS $1.19-$1.26, consensus $1.30 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
Johnson Controls reports Q2 adj. EPS 49c, consensus 49c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
AstraZeneca confirms FY17 core EPS to decline low to mid teens percentage »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

WEX

WEX

$106.85

0.83 (0.78%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
WEX sees FY17 adjusted EPS $5.15-$5.50, consensus $5.33 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PSTB

Park Sterling Bank

$12.52

0.23 (1.87%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Park Sterling Bank »

Park Sterling Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 15

    May

  • 25

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
L3 Technologies reports Q1 diluted cont ops EPS $2.07, consensus $1.81 »

Reports Q1 revenue $2.7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
WEX reports Q1 adjusted EPS $1.23, consensus $1.22 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
AstraZeneca reports Q1 core EPS 99c vs. 95c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
Extended Stay lifts FY17 revenue view to $1.29B-$1.31B from $1.28B-$1.305B 

Consensus $1.3B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Hot Stocks
Breaking Hot Stocks news story on Nintendo »

Nintendo sees FY17 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$5.37

-0.06 (-1.11%)

06:53
04/27/17
04/27
06:53
04/27/17
06:53
Technical Analysis
Nokia trades sharply higher after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:53
04/27/17
04/27
06:53
04/27/17
06:53
Hot Stocks
Nintendo says Switch 'off to a promising start' »

Nintendo Switch, a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQGP

EQT GP

$26.75

-0.39 (-1.44%)

06:52
04/27/17
04/27
06:52
04/27/17
06:52
Hot Stocks
EQT GP increases quarterly distribution 8% to 19.1c per share »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    May

POL

PolyOne

$37.39

-0.02 (-0.05%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
PolyOne reports Q1 adjusted EPS 59c, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
Extended Stay America reports Q1 adj. EPS 15c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.